{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T23:18:49Z","timestamp":1766099929837,"version":"3.48.0"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,12,18]]},"DOI":"10.7759\/cureus.99567","type":"journal-article","created":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T23:13:54Z","timestamp":1766099634000},"source":"Crossref","is-referenced-by-count":0,"title":["Sepsis in a Patient With Atopic Dermatitis Following Upadacitinib Discontinuation"],"prefix":"10.7759","author":[{"given":"John A","family":"Gallagher","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diego","family":"Arag\u00f3n-Caqueo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arhum","family":"Mahmood","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steven","family":"Daveluy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1007\/s00403-021-02219-w","article-title":"Secular trends of atopic dermatitis and its comorbidities in United States children between 1997 and 2018","volume":"314","author":"Hou A","year":"2022","unstructured":"Hou A, Silverberg JI. Secular trends of atopic dermatitis and its comorbidities in United States children between 1997 and 2018. Arch Dermatol Res. 2022, 314:267-74. 10.1007\/s00403-021-02219-w","journal-title":"Arch Dermatol Res"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2018.08.028","article-title":"Atopic dermatitis in America study: a cross-sectional study examining the prevalence and disease burden of atopic dermatitis in the US adult population","volume":"139","author":"Chiesa Fuxench ZC","year":"2019","unstructured":"Chiesa Fuxench ZC, Block JK, Boguniewicz M, et al.. Atopic dermatitis in America study: a cross-sectional study examining the prevalence and disease burden of atopic dermatitis in the US adult population. J Invest Dermatol. 2019, 139:583-90. 10.1016\/j.jid.2018.08.028","journal-title":"J Invest Dermatol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.3238\/arztebl.m2023.0011","article-title":"Atopic dermatitis in children and adults\u2014diagnosis and treatment","volume":"120","author":"Wollenberg A","year":"2023","unstructured":"Wollenberg A, Werfel T, Ring J, Ott H, Gieler U, Weidinger S. Atopic dermatitis in children and adults\u2014diagnosis and treatment. Dtsch Arztebl Int. 2023, 120:224-34. 10.3238\/arztebl.m2023.0011","journal-title":"Dtsch Arztebl Int"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.5414\/ALX02262E","article-title":"Status report on the atopic dermatitis registry TREATgermany","volume":"5","author":"Siegels D","year":"2021","unstructured":"Siegels D, Haufe E, Heinrich L, Werfel T, Weidinger S, Schmitt J. Status report on the atopic dermatitis registry TREATgermany. Allergol Select. 2021, 5:274-86. 10.5414\/ALX02262E","journal-title":"Allergol Select"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-022-00721-1","article-title":"Comparative efficacy of targeted systemic therapies for moderate to severe atopic dermatitis without topical corticosteroids: systematic review and network meta-analysis","volume":"12","author":"Silverberg JI","year":"2022","unstructured":"Silverberg JI, Hong HC, Thyssen JP, et al.. Comparative efficacy of targeted systemic therapies for moderate to severe atopic dermatitis without topical corticosteroids: systematic review and network meta-analysis. Dermatol Ther (Heidelb). 2022, 12:1181-96. 10.1007\/s13555-022-00721-1","journal-title":"Dermatol Ther (Heidelb)"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.3390\/jcm9113741","article-title":"Regulation of skin barrier function via competition between AHR axis versus IL-13\/IL-4-JAK-STAT6\/STAT3 axis: pathogenic and therapeutic implications in atopic dermatitis","volume":"9","author":"Furue M","year":"2020","unstructured":"Furue M. Regulation of skin barrier function via competition between AHR axis versus IL-13\/IL-4-JAK-STAT6\/STAT3 axis: pathogenic and therapeutic implications in atopic dermatitis. J Clin Med. 2020, 9:3741. 10.3390\/jcm9113741","journal-title":"J Clin Med"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2023.08.102","article-title":"Guidelines of care for the management of atopic dermatitis in adults with phototherapy and systemic therapies","volume":"90","author":"Davis DM","year":"2024","unstructured":"Davis DM, Drucker AM, Alikhan A, et al.. Guidelines of care for the management of atopic dermatitis in adults with phototherapy and systemic therapies. J Am Acad Dermatol. 2024, 90:e43-56. 10.1016\/j.jaad.2023.08.102","journal-title":"J Am Acad Dermatol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1080\/03007995.2024.2427883","article-title":"Use of advanced systemic therapy in patients with moderate-to-severe atopic dermatitis in the TARGET-DERM AD Registry","volume":"40","author":"Haft MA","year":"2024","unstructured":"Haft MA, Knapp KD, Claxton A, et al.. Use of advanced systemic therapy in patients with moderate-to-severe atopic dermatitis in the TARGET-DERM AD Registry. Curr Med Res Opin. 2024, 40:2057-66. 10.1080\/03007995.2024.2427883","journal-title":"Curr Med Res Opin"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1080\/14737167.2024.2394124","article-title":"Budget impact and cost per responder analysis of upadacitinib for the treatment of moderate to severe atopic dermatitis from the perspective of the social security and the private sector in Argentina","volume":"25","author":"Espinola N","year":"2025","unstructured":"Espinola N, Rodr\u00edguez Cairoli F, Rojas-Roque C, Luna PC, Kanevsky D, Migliazza V, Pichon-Riviere A. Budget impact and cost per responder analysis of upadacitinib for the treatment of moderate to severe atopic dermatitis from the perspective of the social security and the private sector in Argentina. Expert Rev Pharmacoecon Outcomes Res. 2025, 25:101-11. 10.1080\/14737167.2024.2394124","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.3310\/LEXB9006","article-title":"Abrocitinib, tralokinumab and upadacitinib for treating moderate-to-severe atopic dermatitis","volume":"28","author":"Edwards SJ","year":"2024","unstructured":"Edwards SJ, Karner C, Jhita T, Barton S, Marceniuk G, Yiu ZZ, Wittmann M. Abrocitinib, tralokinumab and upadacitinib for treating moderate-to-severe atopic dermatitis. Health Technol Assess. 2024, 28:1-113. 10.3310\/LEXB9006","journal-title":"Health Technol Assess"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.18553\/jmcp.2022.28.1.108","article-title":"JAK inhibitors and monoclonal antibodies for the treatment of atopic dermatitis: effectiveness and value","volume":"28","author":"Agboola F","year":"2022","unstructured":"Agboola F, Atlas SJ, Brouwer E, et al.. JAK inhibitors and monoclonal antibodies for the treatment of atopic dermatitis: effectiveness and value. J Manag Care Spec Pharm. 2022, 28:108-14. 10.18553\/jmcp.2022.28.1.108","journal-title":"J Manag Care Spec Pharm"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/j.anai.2020.08.002","article-title":"The infectious complications of atopic dermatitis","volume":"126","author":"Wang V","year":"2021","unstructured":"Wang V, Boguniewicz J, Boguniewicz M, Ong PY. The infectious complications of atopic dermatitis. Ann Allergy Asthma Immunol. 2021, 126:3-12. 10.1016\/j.anai.2020.08.002","journal-title":"Ann Allergy Asthma Immunol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/j.anai.2017.10.019","article-title":"Association between atopic dermatitis and serious cutaneous, multiorgan and systemic infections in US adults","volume":"120","author":"Narla S","year":"2018","unstructured":"Narla S, Silverberg JI. Association between atopic dermatitis and serious cutaneous, multiorgan and systemic infections in US adults. Ann Allergy Asthma Immunol. 2018, 120:66-72.e11. 10.1016\/j.anai.2017.10.019","journal-title":"Ann Allergy Asthma Immunol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016\/s0926-9959(98)95291-6","article-title":"Eczema Area and Severity Index (EASI): a new tool to evaluate atopic dermatitis","volume":"11","author":"Tofte S","year":"1998","unstructured":"Tofte S, Graeber M, Cherill R, Omoto M, Thurston M, Hanifin JM. Eczema Area and Severity Index (EASI): a new tool to evaluate atopic dermatitis. J Eur Acad Dermatol Venereol. 1998, 11:197. 10.1016\/s0926-9959(98)95291-6","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1378\/chest.101.6.1644","article-title":"Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP\/SCCM Consensus Conference Committee. American College of Chest Physicians\/Society of Critical Care Medicine","volume":"101","author":"Bone RC","year":"1992","unstructured":"Bone RC, Balk RA, Cerra FB, et al.. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP\/SCCM Consensus Conference Committee. American College of Chest Physicians\/Society of Critical Care Medicine. Chest. 1992, 101:1644-55. 10.1378\/chest.101.6.1644","journal-title":"Chest"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2025.4288","article-title":"Management of Staphylococcus aureus bacteremia: a review","volume":"334","author":"Tong SY","year":"2025","unstructured":"Tong SY, Fowler VG Jr, Skalla L, Holland TL. Management of Staphylococcus aureus bacteremia: a review. JAMA. 2025, 334:798-808. 10.1001\/jama.2025.4288","journal-title":"JAMA"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.19391","article-title":"Upadacitinib treatment withdrawal and retreatment in patients with moderate-to-severe atopic dermatitis: results from a phase 2b, randomized, controlled trial","volume":"37","author":"Guttman-Yassky E","year":"2023","unstructured":"Guttman-Yassky E, Silverberg JI, Tha\u00e7i D, et al.. Upadacitinib treatment withdrawal and retreatment in patients with moderate-to-severe atopic dermatitis: results from a phase 2b, randomized, controlled trial. J Eur Acad Dermatol Venereol. 2023, 37:2558-68. 10.1111\/jdv.19391","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1016\/j.anai.2023.11.009","article-title":"Atopic dermatitis (eczema) guidelines: 2023 American Academy of Allergy, Asthma and Immunology\/American College of Allergy, Asthma and Immunology Joint Task Force on Practice Parameters GRADE- and Institute of Medicine-based recommendations","volume":"132","author":"Chu DK","year":"2024","unstructured":"Chu DK, Schneider L, Asiniwasis RN, et al.. Atopic dermatitis (eczema) guidelines: 2023 American Academy of Allergy, Asthma and Immunology\/American College of Allergy, Asthma and Immunology Joint Task Force on Practice Parameters GRADE- and Institute of Medicine-based recommendations. Ann Allergy Asthma Immunol. 2024, 132:274-312. 10.1016\/j.anai.2023.11.009","journal-title":"Ann Allergy Asthma Immunol"},{"key":"ref19","unstructured":"Uninsured rates highest for young adults aged 19 to 34. (2020). Accessed. September 13, 2025: https:\/\/www.census.gov\/library\/stories\/2020\/10\/uninsured-rates-highest-for-young-adults-aged-19-to-34.html."},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1097\/DER.0000000000000715","article-title":"Financial burden of atopic dermatitis out-of-pocket health care expenses in the United States","volume":"32","author":"Smith Begolka W","year":"2021","unstructured":"Smith Begolka W, Chovatiya R, Thibau IJ, Silverberg JI. Financial burden of atopic dermatitis out-of-pocket health care expenses in the United States. Dermatitis. 2021, 32:S62-70. 10.1097\/DER.0000000000000715","journal-title":"Dermatitis"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.2146\/ajhp060464","article-title":"Patient assistance programs and patient advocacy foundations: alternatives for obtaining prescription medications when insurance fails","volume":"63","author":"Johnson PE","year":"2006","unstructured":"Johnson PE. Patient assistance programs and patient advocacy foundations: alternatives for obtaining prescription medications when insurance fails. Am J Health Syst Pharm. 2006, 63:S13-7. 10.2146\/ajhp060464","journal-title":"Am J Health Syst Pharm"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.2147\/PPA.S101175","article-title":"The impact of patient support programs on adherence, clinical, humanistic, and economic patient outcomes: a targeted systematic review","volume":"10","author":"Ganguli A","year":"2016","unstructured":"Ganguli A, Clewell J, Shillington AC. The impact of patient support programs on adherence, clinical, humanistic, and economic patient outcomes: a targeted systematic review. Patient Prefer Adherence. 2016, 10:711-25. 10.2147\/PPA.S101175","journal-title":"Patient Prefer Adherence"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.18553\/jmcp.2017.16272","article-title":"Impact of a patient support program on patient adherence to adalimumab and direct medical costs in Crohn\u2019s disease, ulcerative colitis, rheumatoid arthritis, psoriasis, psoriatic arthritis, and ankylosing spondylitis","volume":"23","author":"Rubin DT","year":"2017","unstructured":"Rubin DT, Mittal M, Davis M, Johnson S, Chao J, Skup M. Impact of a patient support program on patient adherence to adalimumab and direct medical costs in Crohn\u2019s disease, ulcerative colitis, rheumatoid arthritis, psoriasis, psoriatic arthritis, and ankylosing spondylitis. J Manag Care Spec Pharm. 2017, 23:859-67. 10.18553\/jmcp.2017.16272","journal-title":"J Manag Care Spec Pharm"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.18553\/jmcp.2021.20560","article-title":"Sustained long-term benefits of patient support program participation in immune-mediated diseases: improved medication-taking behavior and lower risk of a hospital visit","volume":"27","author":"Fendrick AM","year":"2021","unstructured":"Fendrick AM, Brixner D, Rubin DT, Mease P, Liu H, Davis M, Mittal M. Sustained long-term benefits of patient support program participation in immune-mediated diseases: improved medication-taking behavior and lower risk of a hospital visit. J Manag Care Spec Pharm. 2021, 27:1086-95. 10.18553\/jmcp.2021.20560","journal-title":"J Manag Care Spec Pharm"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/419365-sepsis-in-a-patient-with-atopic-dermatitis-following-upadacitinib-discontinuation","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T23:14:05Z","timestamp":1766099645000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/419365-sepsis-in-a-patient-with-atopic-dermatitis-following-upadacitinib-discontinuation"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,18]]},"references-count":24,"URL":"https:\/\/doi.org\/10.7759\/cureus.99567","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12,18]]}}}